Carcinogenesis, Vol. 20, No. 7, 1161-1168,
July 1999
© 1999 Oxford University Press
Accelerated Paper |
Taxol, vincristine or nocodazole induces lethality in G1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression
Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Box 69, 1515 Holcombe Boulevard, Houston, TX 77030,
1 Abbott Laboratories, PPD, D-460, AP10-1, 100 Abbott Park Road, Abbott Park, IL 60064 and
2 University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
In this report, we describe a novel lytic mechanism exploited by antimicrotubule drugs (AMDs) such as Taxol which are frequently used to treat multiple human cancers including breast and ovarian cancers. In cells lacking the G1-arresting capacity due to the defect in retinoblastoma or p53 gene function, AMDs trigger hyperploid progression and death. The hyperploid progression occurs via continued cell-cycle progression without cell division. Blocking hyperploid progression through hydroxyurea or ectopically expressed p27Kip1, a G1-specific Cdk inhibitor, abrogates AMD cytotoxicity. Thus, AMDs induce lethality in G1-checkpoint-defective cells by triggering hyperploid progression. The phenomenon is reminiscent of that observed previously with bub-1 yeast mutant. The potential significance of this finding lies in that hyperploid progression-mediated death may be exploited to develop a therapy with tumor-specificity at the genetic level. As a large fraction of human cancers are mutated in p53 gene, it may have a wide therapeutic applicability.
Abbreviations: AMD, antimicrotubule drug; MEF, mouse embryo fibroblast; MT, microtubule; RB, retinoblastoma.
3 To whom correspondence should be addressed Email: fhong{at}notes.mdacc.tmc.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. M. Greene, L. Kelly, V. Onnis, G. Campiani, M. Lawler, D. C. Williams, and D. M. Zisterer STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia Cells J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 288 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, T. Liu, Y. Fang, S. Xie, X. Huang, R. Mahmood, G. Ramaswamy, K. M. Sakamoto, Z. Darzynkiewicz, M. Xu, et al. BUBR1 deficiency results in abnormal megakaryopoiesis Blood, February 15, 2004; 103(4): 1278 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Li, W. Dang, B. M. Tyler, G. Troiano, T. Tihan, H. Brem, and K. A. Walter Polilactofate Microspheres for Paclitaxel Delivery to Central Nervous System Malignancies Clin. Cancer Res., August 1, 2003; 9(9): 3441 - 3447. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Doostzadeh-Cizeron, N. H. A. Terry, and D. W. Goodrich The Nuclear Death Domain Protein p84N5 Activates a G2/M Cell Cycle Checkpoint Prior to the Onset of Apoptosis J. Biol. Chem., January 5, 2001; 276(2): 1127 - 1132. [Abstract] [Full Text] [PDF] |
||||



